Cooper Consumer Health Poised To Double In Size With Viatris Acquisition

Cooper Consumer Health says it is set to become a “truly pan-European pure-play leader in consumer healthcare” with the acquisition of Viatris' OTC business in a $2.2bn deal.

M&A written on red and blue blocks
• Source: Shutterstock

Cooper Consumer Health is poised to expand substantially with the acquisition of Viatris’ OTC business.

More from Deals

Schwabe Taps Into Younger Audience With Braineffect Deal

 
• By 

By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.

Herbalife Spends To Add Personalized Supplements Through Nutrition App, Enter Ketone Market

 

Direct seller has deals to fully acquire and 51% ownership of Link BioSciences, which formulates personalized supplements. It also announced a deal to acquire Pruvit Ventures, ketone supplements direct seller.

SFI Expands Distribution Of Brain Health Supplement In Europe

 
• By 

Australia's SFI Health looking to take Equazen omega-3 fatty acids supplement to new markets to capitalize on Europe's fast-growing brain health segment.

Doc Generici Becomes DOC Pharma As Diversification Continues

 
• By 

A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.

More from Business

Swisse Benefits As Supplements Considered ‘Daily Necessity’ In China

 
• By 

Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.

OptiBiotix Benefitting From Popularity Of Anti-Obesity Drugs

 
• By 

Growing use of GLP-1 receptor agonists is having a positive knock-on effect on the dietary supplements market, reports OptiBiotix Health, marketer of the SlimBiome weight management prebiotic.

Schwabe Taps Into Younger Audience With Braineffect Deal

 
• By 

By taking a majority stake in dynamic dietary supplements firm Braineffect, Germany's Schwabe can reach a new, younger target audience for its OTC herbal medicines.